drugset

drugset / Trial / NCT00235560

Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients

NCT00235560 ↗

Phase 2 Completed 50 enrolled University Hospital, Toulouse French Innovative Leukemia Organisation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.

Timeline

Start: 2005-06
Primary completion: 2008-06
Completion: 2008-06

Publications

Background Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005 Mar 15;105(6):2527-34. doi: 10.1182/blood-2004-06-2494. Epub 2004 Nov 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rapamycin	Small molecule	—	—

Indications